Moderna mRNA Cancer Vaccine Meets Phase 3 Trial Endpoints

Moderna and Merck & Co. announced that their personalized mRNA cancer vaccine, intismeran autogene, met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in a Phase 3 trial. The study involved 1,137 patients with surgically removed high-risk melanoma and reported no new safety concerns.

The clinical success triggered a 177% surge in Moderna's share price, raising its market capitalization to approximately $60 billion. The results also sparked a 21.6% rally for BioNTech SE, as the trial provided broad evidence that mRNA technology can be effective against cancer in large late-stage trials. However, analysts noted that the results are not a direct clinical read-through for BioNTech's specific pipeline due to differences in manufacturing and antigens.

Despite the trial success, Moderna reported a $782 million GAAP net loss for the second quarter of 2026. To fund further oncology development, the company announced a $2 billion convertible-notes offering on August 27, maintaining a target for cash breakeven by 2028. While the platform is validated, the vaccine still requires regulatory approval and the resolution of logistical and manufacturing challenges before it can reach patients.